HSBC Discount Zert 22UA 30.12.202.../ DE000HG98QS9 /
11/15/2024 6:00:09 PM | Chg.-0.100 | Bid6:40:07 PM | Ask6:40:07 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
70.440EUR | -0.14% | 70.400 Bid Size: 15,000 |
70.520 Ask Size: 15,000 |
BIONTECH SE SPON. AD... | - - | 12/30/2024 | Call |
GlobeNewswire
8/22
Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vacc...
GlobeNewswire
8/16
Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and C...
GlobeNewswire
7/30
BioNTech Announces Positive Topline Phase 2 Results for mRNA Immunotherapy Candidate BNT111 in Patie...
GlobeNewswire
7/22
BioNTech to Report Second Quarter 2024 Financial Results and Corporate Update on August 5, 2024
GlobeNewswire
6/27
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the E...
GlobeNewswire
6/24
BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT...
GlobeNewswire
6/1
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates M...
GlobeNewswire
5/29
BioNTech and CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine Ecosystem
GlobeNewswire
5/21
BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO A...
GlobeNewswire
5/17
BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024
GlobeNewswire
4/22
BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024
GlobeNewswire
4/7
Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persis...
GlobeNewswire
3/20
BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
GlobeNewswire
3/20
BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer
GlobeNewswire
3/11
BioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidat...
GlobeNewswire
3/6
BioNTech to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update ...